REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM)

July 28, 2026: Plus Therapeutics, Inc. (NASDAQ: PSTV) announced two poster presentations and a sponsored symposium at the 2026 SNO/ASCO CNS Metastases Conference (Aug. 13–15, 2026, Boston). The posters cover (1) the ReSPECT-LM program evaluating rhenium obisbemeda/REYOBIQ for leptomeningeal metastases, including a pharmacokinetic/pharmacodynamic assessment with “emerging data from repeated dosing” (ReSPECT-LMM), and (2) a cost-of-care analysis on the economic impact of earlier detection and therapeutic management of leptomeningeal metastases using the CNSide® CSF diagnostic platform. Both posters are scheduled for Aug. 13, 2026 (7:15–9:00 PM ET).

The company will also host a sponsored symposium on Aug. 13, 2026 (6:15–7:15 PM ET) focused on leptomeningeal metastases management, including CSF biomarkers, emerging therapies, and roles for data analytics/AI.

Plus said it will formally introduce a new corporate identity, Cerenome, and stated it will change its name to Cerenome, Inc. effective Aug. 3, 2026 and begin trading under Nasdaq ticker CNSY (from PSTV).